Suzanne Garland
IPVS Immediate Past President
Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Department of Microbiology, RCH Honorary Research Fellow, Murdoch Childrens Research Institute Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia
Anna Giuliano
IPVS President
Anna-Barbara Moscicki
IPVS President Elect
Dr. Moscicki is Professor of Pediatrics at UCLA, Chief, Division of Adolescent and Young Adult Medicine, Associate Executive Chair for Clinical Research, and Chair, Clinical Trials Committee for Pediatrics. Dr. Moscicki’s 35+ year career has focused on adolescent gynecology and sexually transmitted infection research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. Dr. Moscicki was the principle investigator of a natural history study of HPV in adolescents and young women that followed women for 25 years, one of the longest running HPV cohorts. Her work on the natural history included defining persistence and clearance, mucosal and systemic immune responses to HPV and the role of the microbiome and HPV clearance. She has served on numerous national and international committees, including the W.H.O., N.I.H., American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Cancer Society. She is a Past President of ASCCP. Her work was highly influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women in the US. She is also involved in health outcomes in perinatally HIV infected children including sexual risk behaviors, substance use, oral health, microbiomes, and HPV and has worked with numerous Networks on HIV disease in children and adolescents. She was a working group chair for the new ASCCP Risk-Based Management Guidelines.
Aimeé Kreimer
IPVS Secretary
Dr. Kreimer is a Senior Investigator at the US National Cancer Institute, Division of Cancer Epidemiology and Genetics. She focuses her research on the etiology and prevention of human papillomavirus (HPV) and cancers at multiple sites, including the head and neck and anogenital region. She has particular interests in translational research, cancer etiology related to the natural history of HPV infection at multiple anatomic sites, and cancer prevention. She leads investigations on associations between HPV serostatus and risk of HPV-driven oropharyngeal cancers. She is the Principal Investigator on several prophylactic HPV vaccine trials including “ESCUDDO: A Randomized Trial of One-Dose HPV Vaccination,” a research initiative of the Cancer Moonshot.
Cary Moody
IPVS Treasurer
Dr. Moody is an Associate Professor in the Department of Microbiology and Immunology at the University of North Carolina-Chapel Hill. She is also a member of the Lineberger Comprehensive Cancer Center. She is the Co-Director of the NIH NIAID NRSA-Funded “Molecular Biology of Viral Diseases” T32 training program.
Dr. Moody received a B.S. and M.S. in Microbiology from Mississippi State University in 1997 and 1999, respectively. She received a PhD in Microbiology from Louisiana State University Health Sciences Center-Shreveport in 2004. She completed her post-doctoral training with Dr. Lou Laimins at Northwestern University School of Medicine from 2005-2010. Dr. Moody joined the faculty of the UNC-Chapel Hill School of Medicine in 2010.
Research in Dr. Moody’s lab focuses on understanding how cancer-associated HPVs alter the host cell during the different stages of the viral life cycle to promote viral replication. Her studies aim to identify cellular signaling pathways commandeered by HPV to facilitate viral DNA synthesis and to determine the impact of modifying the cellular environment on host genomic stability. Dr. Moody’s research has been continuously funded by the U.S. NIH since 2010. Her work has also been supported by a Research Scholar Grant from the American Cancer Society.
Andreia Albuquerque
Board Member
Dr. Andreia Albuquerque, MD, PhD, is a Consultant Gastroenterologist and Associate Professor with a keen focus on early detection and the prevention of anal cancer. She has authored over 80 peer-reviewed publications, including first-author contributions in The Lancet Gastroenterology and Hepatology, Journal of Crohn’s and Colitis, Clinical Infectious Diseases, British Journal of Cancer, and the International Journal of Cancer.
Dr. Albuquerque currently serves as a Board Member of the International Papillomavirus Society (IPVS), chairs the IPVS Social Media Committee, and is a member of the IPVS Education Committee. She also co-directed the inaugural edition of the IPVS Human Papillomavirus-Related Anogenital Diseases Course for Clinicians (IPVS PACC) and the IPVC 2024 High-Resolution Anoscopy Workshop.
Laila Sara Arroyo Mühr
Board Member
Dr. Sara Arroyo is a Tumor Biologist and Scientific Lead at the International Human Papillomavirus (HPV) Reference Center, Karolinska Institutet. Her research focuses on HPV-associated cancers, leveraging molecular biology, next-generation sequencing, and machine learning to advance cancer prevention and screening. Dr. Arroyo oversees the Global HPV LabNet, a worldwide network of national HPV reference laboratories dedicated to global standardization and quality assurance in HPV diagnostics. She coordinates key initiatives, including Sweden’s cervical cancer elimination project, and leads pioneering efforts such as self-sampling programs in conflict-affected regions like Ukraine. Dr. Arroyo is a recognized expert in risk-based screening and HPV diagnostics.
Ann Burchell
Board Member
Dr. Ann Burchell, Canada Research Chair in Sexually Transmitted Infection Prevention, uses epidemiological data to improve prevention and health care for HPV, HIV, and other STIs and minimize the complications associated with these diseases. She and her research team hope to promote sexual health for all by supporting effective and practical strategies to prevent STIs and related cancers in high-risk populations. Dr. Burchell is a scientist with MAP Centre for Urban Health Solutions in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, and Research Director of St. Michael’s Department of Family and Community Medicine. She is also a scientist with ICES, an Associate Professor in the University of Toronto’s Faculty of Medicine (Department of Family and Community Medicine) and Dalla Lana School of Public Health (Division of Epidemiology).
Kimon Chatzistamatiou
Board Member
Dr. Kimon Chatzistamatiou is an academic consultant in the 1st Department of Obstetrics and Gynecology at the Aristotle University of Thessaloniki, Greece. He received his MD (2002) and PhD (2017) from the Medical School of the Aristotle University of Thessaloniki. He is board-certified in Obstetrics and Gynecology (2013), certified in colposcopy and cervical pathology (2014), and has overseen the lower genital tract clinic at “Papageorgiou” General Hospital in Thessaloniki, Greece, since 2018.
Kate Cuschieri
Board Member
Dr. Andreia Albuquerque, MD, PhD, is a Consultant Gastroenterologist and Associate Professor with a keen focus on early detection and the prevention of anal cancer. She has authored over 80 peer-reviewed publications, including first-author contributions in The Lancet Gastroenterology and Hepatology, Journal of Crohn’s and Colitis, Clinical Infectious Diseases, British Journal of Cancer, and the International Journal of Cancer.
Dr. Albuquerque currently serves as a Board Member of the International Papillomavirus Society (IPVS), chairs the IPVS Social Media Committee, and is a member of the IPVS Education Committee. She also co-directed the inaugural edition of the IPVS Human Papillomavirus-Related Anogenital Diseases Course for Clinicians (IPVS PACC) and the IPVC 2024 High-Resolution Anoscopy Workshop.
Ida Ismail-Pratt
Board Member
Dr Ida graduated from Glasgow University and obtained her specialist accreditation, MRCOG, in the United Kingdom in 2010. She recently obtained her fellowship from the Royal College of O&G (UK). She is a BSCCP (British Society of Colposcopy and Cervical Pathology) accredited colposcopist and currently President of SCCPS (Society of Colposcopy &Cervical Pathology Singapore). She was previously a Consultant ObGyn & led the Gynaecology Cancer Screening and Prevention services in National University Hospital (NUH). During that time, Dr Ida championed the introduction of HPV DNA testing as an alternative for cervical cancer screening in 2014.She was co-chairman for the Cervical Screen Singapore (CSS) Implementation Committee that was responsible in implementing HPV Primary Screening in Singapore in May 2019 and currently lead the CSS Clinical Guideline Review Group in updating cervical cancer screening practice in Singapore. Dr. Ida is also active internationally in education and training of doctors mainly in the LMIC. She co-led and co-develop the International Gynaecology Cancer Society (IGCS) preinvasive Disease certificate Program which was created especially to aid in developing skilled preinvasive cervical disease practitioners in low- and middle-income countries (LMIC). She has helped to develop various preinvasive and colposcopy training in Vietnam, Cambodia, Myanmar and Malaysia. She leads the International Papillomavirus Society (IPVS) ECHO committee that gives a support platform for doctors especially in the LMIC on management of HPV related cases. She is also the Secretary for the Asia Pacific HPV coalition who are currently actively establishing implementation studies on introduction of HPV self-sampling to LMICs. This year, she has been awarded the International Gynaecology Cancer Society (IGCS) Global Humanitarian Award for her work in the LMIC in cervical cancer prevention efforts.
Racheal Mandishora
Board Member
Dr Racheal S. Dube Mandishora is a trained Molecular Virologist and Cancer Epidemiologist. She has developed a strong research profile focused on the biology of oncoviruses, such as Human Papillomavirus (HPV), and their synergistic cooperation with other microorganisms in contributing to human diseases and cancers. Racheal has led and co-investigated studies on the molecular characterization and prevalence of HPV across various anatomical sites—including cervico-vaginal, anal, vulval, and ocular regions—in the Zimbabwean population, with an emphasis on infection rates in people living with HIV (PLWH). She is currently analyzing data from the HPV in Men (HIM) study cohort to explore oral HPV acquisition patterns and the associated risk factors among men from the USA and Latin America. With a background in wet laboratory Medical Science, Racheal combines her Basic Science and Epidemiology expertise to investigate the role of HPV variants at both lineage and sublineage levels. Her research also examines HPV whole genome diversity in women living with HIV, particularly in the context of multi-anatomical site cancers. Racheal’s long-term goal is to translate these findings into clinical practice, contributing to more effective HPV related cancer preventative and diagnostic tools.
Dr Racheal S. Dube Mandishora, a native Zimbabwean based in the USA, has actively mobilized researchers from Low- and Middle-Income Countries (LMICs) to become members of the International Papillomavirus Society (IPVS), through the ambassador program. She maintains a strong presence in cancer awareness, in her home country, and has organized HPV workshops and laboratory trainings, fostering collaboration between senior IPVS researchers and early-career scientists from the Southern African region. This work demonstrates her commitment to capacity building and research visibility in the global fight against HPV-related cancers.
Mariano Molina
Board Member
Mariano Molina, PhD, is a Postdoctoral Researcher at Karolinska Institutet, where he investigates circulating bacterial extracellular vesicles (BEVs) as liquid biopsy biomarkers for multi-cancer early detection. His work integrates microbiology, liquid biopsies, and multiomics approaches to improve early cancer detection.
Originally from Panama, he earned his Bachelor’s degree in Medical Technology from Universidad Latina de Panamá, followed by an MSc in Microbiology at Radboud University in the Netherlands, with research stays in the United States and Canada. He also completed his PhD in Medical Sciences at Radboud University, where he studied the cervicovaginal microbiome and its relationship to high-risk HPV infections, contributing with high-resolution sequencing methods to advance the field. After his PhD, he completed a postdoctoral training at Amsterdam UMC focused on RNA-based liquid biopsy biomarkers for cervical cancer.
Mariano is an active member of the International Papillomavirus Society (IPVS), where he also serves as a Board Member, Chair of the Early Career Committee, and Member of the Social Media Committee.
Karl Munger
Board Member
Karl Munger earned his bachelor’s and Ph.D. degrees in Biochemistry from the University of Zurich in Switzerland. He currently serves as the Dorothy Todd Bishop Research Professor and Chair of the Department of Developmental, Molecular, and Chemical Biology at Tufts University School of Medicine. Dr. Munger’s research is centered on understanding the molecular mechanisms by which human papillomaviruses contribute to carcinogenesis.
In addition to his research, Dr. Munger is deeply dedicated to education and mentorship. Over the course of his career, he has held numerous leadership roles in initiatives aimed at making biomedical research training more accessible and appealing to individuals from groups underrepresented in the biomedical sciences.
Chemtai Mungo
Board Member
Dr. Chemtai Mungo is an Assistant Professor of Obstetrics, Gynecology, and Global Health at the University of North Carolina in the United States. She was born and raised in Kenya and did her undergraduate and medical training in the United States. Dr. Mungo is passionate about using research, advocacy, and capacity-building to pursue global women’s health equity. Her research is focused on increasing access to effective, evidence-based secondary prevention of cervical cancer in Africa, particularly focused on women living with HIV.
Dr. Mungo received a bachelor’s degree with Honors from the University of California in Berkeley. She received her medical degree from the University of California, San Francisco, where she graduated with Distinction in Clinical and Translational Research. She also completed a master’s in public health from the Johns Hopkins School of Public Health. Dr. Mungo has published seventeen peer-reviewed manuscripts in international journals and is leading several clinical trials evaluating the feasibility of using topical, self-administered therapies for HPV and cervical precancer treatment in low-resource settings. She was named a Young Cancer Leader in 2021 by the Union of International Cancer Control and, in 2022, received the Victoria’s Secret Global Fund for Women’s Cancers Career Development Award. Her research is also funded by the National Institute of Health (U.S.A) and the University of North Carolina Lineberger Comprehensive Cancer Center. Dr. Mungo is motivated by her experiences growing up in a small town in Kenya and witnessing the health impact of weak health systems among women already facing the double burden of poverty and patriarchy.
Laura Sichero
Board Member
Research Coordinator at the Cancer Institute of the State of São Paulo and a Collaborator Professor at the Faculty of Medicine, University of São Paulo (USP), São Paulo, Brazil. I have a broad background in Molecular Virology, with specific training and expertise in molecular biology, molecular epidemiology, and biochemistry. Research focuses on the understanding of the impact of mucosal and cutaneous HPV genetic variability upon associated disease development and biological and biochemical properties of infected cells. Further involved in studying HPV transcription and the use of transcription factors as prognostic biomarkers and therapeutic targets.
Joel Palefsky
Honorary Board Member
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is the founder and director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is the immediate past president of the International Papillomavirus Society and is the founder and immediate past president of the International Anal Neoplasia Society. He is a member of the ASCI and AAP. His research interests include the molecular pathogenesis and natural history of HPV-related disease, including in the setting of HIV infection, HPV prophylactic and therapeutic vaccines, secondary prevention of anal cancer, and treatment of HPV-related disease.
Anna Daniela Iacobone
ECR Affiliate Board Member
Dr. Anna Daniela Iacobone is a gynecologist with a PhD in Biomedical Sciences, specializing in Public Health. She has extensive expertise in the prevention, diagnosis, and treatment of lower genital tract diseases, with a particular focus on HPV-related conditions, vulvar pathology, and laser surgery. Her competencies also include the fertility-sparing management of early-stage cervical and endometrial cancers in young women.
Dr. Iacobone currently practices at the European Institute of Oncology in Milan, Italy, where she leads research initiatives in HPV-related diseases. She is widely recognized for her contributions to clinical research on HPV testing, test-of-cure strategies, and self-sampling methodologies. In addition to her clinical and research work, she has a strong academic presence, lecturing in advanced university programs and publishing extensively in peer-reviewed journals.
An active member of several Italian societies for cervical screening, colposcopy, and vulvar pathology, Dr. Iacobone has been a Fellow of the International Society for the Study of Vulvovaginal Disease since September 2019.
Federica Inturrisi
ECR Affiliate Board Member
Dr. Federica Inturrisi is an epidemiologist with a special interest on cervical cancer prevention.
She holds a bachelor degree in Biology (2011) from the University of Catania, Italy, a master degree in Molecular Biosciences – major Cancer Biology (2014) from the German Cancer Research Center (DKFZ) and the University of Heidelberg, Germany, and a master degree in Epidemiology and Biostatistics (2016) from the Università Cattolica del Sacro Cuore in Rome, Italy. In 2022, she completed her PhD in Epidemiology at VU University Amsterdam, the Netherlands.
Her PhD contributed to the Horizon 2020 RISCC project, focusing on optimizing cervical cancer screening through risk-based strategies in European settings. Her work included evaluating self-sampling as a primary screening method in the Dutch national program and risk stratification based on HPV genotyping, past screening results and HPV vaccination status.
Since 2022, Dr. Inturrisi has been working with the US National Cancer Institute (NIH/NCI) on the PAVE project, driving efforts to advance secondary prevention of cervical cancer in resource-limited settings. As part of this large effort in nine LMICs, Dr. Inturrisi works on the self-sampling and HPV extended genotyping components, contributes to the AI-driven visual evaluation, and supports with coordination of the clinical sites and collaboration with the commercial partners. She also serves as the referent person for study sites in sub-Saharan Africa (Tanzania, Malawi, Eswatini) and spent a year in Tanzania supporting fieldwork and collaborating on national cervical cancer prevention policies.
Richard Hillman
Senior Affiliate Board Member
Professor Richard Hillman runs the Dysplasia & Anal Cancer Services within the Department of HIV & Immunology, St Vincent’s Hospital, Sydney. He developed High Resolution Anoscopy in Sydney during the initial efficacy trials for Gardasil in 2004. Since then, he has been President of the International Anal Neoplasia Society, where he was involved in the development of international guidelines for High Resolution Anoscopy, and anal cancer screening. He has published over 140 peer-reviewed articles, including in the Lancet and New England Journal of Medicine.
Richard Roden
Senior Affiliate Board Member
Richard Roden, PhD, is a Professor in the Departments of Pathology, Gynecology and Obstetrics, and Oncology at the Johns Hopkins University School of Medicine. He has co-led the Johns Hopkins Kimmel Cancer Center’s Cancer Prevention and Control Program for 10 years. His research focuses on approaches to prevent and treat cervical cancer through the development of novel vaccines and small molecule proteasome inhibitors. Dr. Roden’s team is currently engaged in the early clinical development of a minor capsid antigen L2-based vaccine that is active against all oncogenic types of human papillomavirus (HPV). He is also working on immunotherapy phase I trials to test their potential to treat HPV infections and dysplasia, thereby interrupting progression to cervical cancer.
Sadeep Shrestha
Senior Affiliate Board Member
Dr. Shrestha is a Professor in the Department of Epidemiology, School of Public Health, University of Alabama at Birmingham. He is a recipient of the Quetelet Endowed Professorship in Public Health that was awarded in 2018. He is the director of the Program in Epidemiology of Inflammation, Infection, and Immunity (PEIII) and has established epidemiology and genomic research programs of various infection related diseases, including STIs (specifically HIV and HPV). He has particular interest in understanding the biology and risk factors of HPV persistence and associated pre-cancer lesions and cancers (cervical, oropharyngeal, anal, and penile). Dr. Shrestha has also initiated a cervical cancer screening program in Nepal, in collaboration with multiple stakeholders including local governments, academic institutes, and a local NGO with tremendous outreach access. In addition to his research, Dr. Shrestha is extremely dedicated to education and mentorship in US, Nepal and globally.
Marc Steben
Senior Affiliate Board Member
Dr. Marc Steben is a family doctor at the Family medicine Group la Cité du parc Lafontaine. He is president elect of the 2023 International Society for STD research. He is a member of the Board and chair for the Education Committee of the International Papillomavirus Society. He is chair of the Canadian Network for HPV Prevention. He is the elected president of the Canadian branch of the International Union Against STIs for 2023. He is a member of the Board of the American Sexual Transmitted Association. He is associate editor of the Journal of Obstetrics and Gynecology of Canada. He is professor at the School of Public Health at Université de Montréal. He is co-chairman of HPV Global Action. He is a member of the PAVE consortium of the National Cancer Institute of the American NIH.
Theodoros Agorastos
Board member
Dr. Staci Sudenga is an Assistant Professor of Medicine in the Division of Epidemiology at Vanderbilt University Medical Center. She is the Chair of the Social Media Committee for the International Papillomavirus Society.
Dr. Sudenga’s research focuses on the molecular epidemiology of cancers associated with infections, particularly among diverse populations with altered immunity, including individuals with HIV. Her work aims to identify biomarkers that can inform cancer prevention and treatment strategies.
Staci Sudenga
Social Media Committee Chair, Board member
Dr. Staci Sudenga is an Assistant Professor of Medicine in the Division of Epidemiology at Vanderbilt University Medical Center. She is the Chair of the Social Media Committee for the International Papillomavirus Society.
Dr. Sudenga’s research focuses on the molecular epidemiology of cancers associated with infections, particularly among diverse populations with altered immunity, including individuals with HIV. Her work aims to identify biomarkers that can inform cancer prevention and treatment strategies.